LEDERMAN SETH (Chief Executive Officer) purchased 22.2% of their position (2K shares) of TONIX PHARMACEUTICALS HOLDING CORP. on the open market
Open‑market purchase worth $27.6K — a significant purchase. The strongest form of insider conviction signal.
P · 1 purchase
Filed: 8/31/2026ACC: 0001493152-26-040736
DirectorOfficer· Chief Executive Officer
Since Jun 2018
+2K
Net shares
Net buyer
$27.6K
Total acquired
1
Open market trades
1B · 0S
1
Total transactions
2K acquired
Non-Derivative Transactions1
Common Stock, $0.001 par value
Indirect
Shares
+2K
Price / share
$13.79
Trade value
$27.58K
% of position
22.2%
8/27/2026
9.01K→11.01K
Total
Net shares
+2K
Net value
$27.58K
| Security | Date | Type | Shares | Price / Share | Trade Value | % of Position | Held Before | Held After |
|---|---|---|---|---|---|---|---|---|
| Common Stock, $0.001 par value Indirect | 8/27/2026 | P · Purchase | +2K | $13.79 | $27.58K | 22.2% | 9.01K | 11.01K |
| Total | +2K | $27.58K | ||||||
Derivative Transactions0
No derivative transactions reported
Non-Derivative Holdings (Post-Transaction)2
Common Stock, $0.001 par value
DirectShares owned20K
Common Stock, $0.001 par value
IndirectShares owned1.00
Total
20K direct·1.00 indirect20K
| Security Title | Shares Owned | Ownership Type |
|---|---|---|
| Common Stock, $0.001 par value | 20K | Direct |
| Common Stock, $0.001 par value | 1.00 | Indirect |
| Total | 20K | 20K direct·1.00 indirect |
Derivative Holdings (Post-Transaction)0
No derivative holdings reported